Skip to main content
Top

Open Access 10-05-2024 | Benzodiazepine | REVIEW

Fake Xanax: Designer Emerging Benzodiazepine Epidemic Linked to Morbidity and Mortality a Narrative Review

Authors: Alan D. Kaye, Joseph P. Tassin, William C. Upshaw, Camille M. Robichaux, Mark V. Frolov, Mark M. Dupaquier, Julia E. Fox, Jeffrey Sterritt, Jibin Mathew, Sahar Shekoohi, Adam M. Kaye, Amber N. Edinoff

Published in: Neurology and Therapy

Login to get access

Abstract

Etizolam is a thienodiazepine derivative which produces an anxiolytic effect similar to benzodiazepines such as alprazolam (Xanax). Like classic benzodiazepines, etizolam has a high affinity towards the GABAA receptor, and allosterically potentiates the effects of GABA resulting in neuronal hyperpolarization related to chloride influx. When taken in therapeutic doses, etizolam produces a similar effect to Xanax. Counterfeit Xanax tablets contain variable amounts of etizolam. Tablets with high amounts of etizolam can cause toxicity if ingested, especially when combined with other substances. When toxic symptoms occur in patients, they may include severe sedation, unconsciousness, and depression of the medullary respiratory center. In this regard, there is the potential for death. Additionally, the rise in fake Xanax tablets containing etizolam and other counterfeit medications has been exacerbated by the difference in regulations regarding these substances in different countries as well as the illegal drug trade. Healthcare providers may also play a role through the over- or underprescribing of certain medications. Thus, in order to combat the rise in counterfeit medications such as fake Xanax, international cooperation, regulation, and enforcement of laws pertaining to the manufacture, prescription, and distribution of these substances are needed.
Literature
12.
go back to reference Dowd FJ. In: Johnson BS, Mariotti AJ, editors. Pharmacology and therapeutics for dentistry. 7th edition. Elsevier; 2017. Dowd FJ. In: Johnson BS, Mariotti AJ, editors. Pharmacology and therapeutics for dentistry. 7th edition. Elsevier; 2017.
23.
go back to reference Beigmohammadi MT, Hanifeh M, Rouini MR, Sheikholeslami B, Mojtahedzadeh M. Pharmacokinetics alterations of midazolam infusion versus bolus administration in mechanically ventilated critically ill patients. Iran J Pharm Res. 2013;12(2):483–8.PubMedPubMedCentral Beigmohammadi MT, Hanifeh M, Rouini MR, Sheikholeslami B, Mojtahedzadeh M. Pharmacokinetics alterations of midazolam infusion versus bolus administration in mechanically ventilated critically ill patients. Iran J Pharm Res. 2013;12(2):483–8.PubMedPubMedCentral
29.
39.
go back to reference Edinoff AN, Nix CA, Odisho AS, et al. Novel designer benzodiazepines: comprehensive review of evolving clinical and adverse effects. Neurol Int. 2022;14(3):648–63.CrossRefPubMedPubMedCentral Edinoff AN, Nix CA, Odisho AS, et al. Novel designer benzodiazepines: comprehensive review of evolving clinical and adverse effects. Neurol Int. 2022;14(3):648–63.CrossRefPubMedPubMedCentral
Metadata
Title
Fake Xanax: Designer Emerging Benzodiazepine Epidemic Linked to Morbidity and Mortality a Narrative Review
Authors
Alan D. Kaye
Joseph P. Tassin
William C. Upshaw
Camille M. Robichaux
Mark V. Frolov
Mark M. Dupaquier
Julia E. Fox
Jeffrey Sterritt
Jibin Mathew
Sahar Shekoohi
Adam M. Kaye
Amber N. Edinoff
Publication date
10-05-2024
Publisher
Springer Healthcare
Published in
Neurology and Therapy
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI
https://doi.org/10.1007/s40120-024-00628-3